Cerus' INTERCEPT Blood System Receives CE Mark Label Expansion for Treatment of Previously...

Tue Aug 12, 2008 6:00am EDT

* Reuters is not responsible for the content in this press release.

Cerus' INTERCEPT Blood System Receives CE Mark Label Expansion for Treatment of Previously Frozen Plasma

CONCORD, Calif.--(Business Wire)--
Cerus Corporation (NASDAQ:CERS) announced today that it has
received an expanded label claim allowing the use of its INTERCEPT
Blood System(TM) to treat previously frozen plasma. Under the expanded
claim, blood banks in countries that recognize the CE mark may now use
INTERCEPT pathogen inactivation to treat either previously frozen or
freshly collected plasma. This increases the supply of plasma
available for pathogen inactivation by allowing treatment of imported
plasma and plasma in quarantined inventory, both of which are
previously frozen. In addition, the change also aids INTERCEPT
customers who collect plasma over larger geographic regions, allowing
plasma to be frozen after donation in remote collection locations and
treated later at component processing centers. Cerus received CE mark
registration for the INTERCEPT Blood System for platelets in 2002 and
for plasma in 2006. The INTERCEPT system is used in blood centers in
Europe, Russia and the Middle East.

   "We are committed to expanding the scope of the INTERCEPT Blood
System for use in various types of blood components," said Larry
Corash, senior vice president and chief medical officer of Cerus
Corporation. "Customers can have confidence when using INTERCEPT for
pathogen inactivation, based upon Cerus' clinical trial data for each
major plasma indication showing that INTERCEPT-treated plasma has
therapeutic efficacy comparable to conventional plasma. Pathogen
inactivation is an important safeguard to prevent infections in
patients receiving blood transfusions."


   The INTERCEPT Blood System is designed to reduce the risk of
transfusion-transmitted diseases by inactivating a broad range of
pathogens, such as viruses, bacteria and parasites, as well as harmful
white blood cells that may be present in donated blood intended for
transfusion. The system inactivates pathogens in platelets and plasma
using a proprietary illumination device, process and active compound.
The INTERCEPT Blood System is designed to be easily incorporated into
the typical operations of blood banks and to provide protection
against a broad spectrum of known and emerging pathogens. The
INTERCEPT Blood System has received CE mark approvals for both the
platelet and plasma systems. No pathogen inactivation system has been
shown to inactivate all pathogens. For more information on the
INTERCEPT Blood System visit www.interceptbloodsystem.com.


   Cerus Corporation is a biomedical products company focused on
commercializing the INTERCEPT Blood System to enhance blood safety.
The INTERCEPT Blood System is designed to inactivate blood-borne
pathogens in donated blood components intended for transfusion. Cerus
currently markets the INTERCEPT Blood System for both platelets and
plasma in Europe and the Middle East. The Company is also pursuing
regulatory approvals in the United States and other countries. The
INTERCEPT red blood cell system is currently in clinical development.
For more information on Cerus Corporation or the INTERCEPT Blood
System visit www.cerus.com.

   INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus

Cerus Corporation
William J. Dawson
Vice President, Finance & CFO
Porter Novelli Life Sciences
Jason I. Spark, 619-849-6005

Copyright Business Wire 2008
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.